Skip to main content
Haisco Pharmaceutical Group Co.,Ltd logo

Haisco Pharmaceutical Group Co.,Ltd — Investor Relations & Filings

Ticker · 002653 ISIN · CNE100001BC7 LEI · 300300GRLH34A8GPJ639 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,439 across all filing types
Latest filing 2024-10-11 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002653

About Haisco Pharmaceutical Group Co.,Ltd

https://www.haisco.com

Haisco Pharmaceutical Group Co.,Ltd. focuses on the research, development, production, and commercialization of innovative drugs and high-end generic pharmaceuticals. The company maintains a specialized portfolio across therapeutic areas including anesthesia, parenteral nutrition, anti-infection, cardiovascular health, and endocrine disorders. Key products include advanced anesthetic agents and specialized nutritional injections designed for clinical use. Haisco prioritizes technological innovation through a dedicated R&D infrastructure, targeting the development of small molecule chemical drugs and complex delivery systems. Its operations emphasize high-standard manufacturing processes and the integration of clinical research to address complex medical requirements. The company aims to provide therapeutic solutions that enhance patient care through a commitment to scientific excellence and product quality.

Recent filings

Filing Released Lang Actions
关于在英属维尔京群岛和开曼分别设立全资子公司进展情况的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the establishment of wholly-owned subsidiaries in the British Virgin Islands and the Cayman Islands by the company 海思科医药集团股份有限公司. It details the approval by the board, the registration completion, and the basic information of the new subsidiaries. There is no financial data, no report attached or referenced as being published, and no mention of voting results or management changes beyond the establishment of subsidiaries. This fits the category of a general regulatory announcement about corporate structure changes but not a full management change announcement or capital change (since it does not mention share issuance or capital structure changes). Given the nature of the announcement and the lack of fit with other categories, the best classification is Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2024-10-11 Chinese
关于2024年限制性股票激励计划授予完成的公告
Share Issue/Capital Change Classification · 95% confidence The document is an announcement regarding the completion of the 2024 restricted stock incentive plan grant by the company 海思科医药集团股份有限公司. It details the number of shares granted, the recipients, approval procedures, performance targets, and the impact on share capital and earnings per share. The document is a formal public announcement of a capital change related to stock incentives, including share issuance and changes in share capital structure. It does not contain financial statements or detailed financial performance data but focuses on the stock incentive plan grant completion and related share capital changes. Therefore, it fits best under the category of Share Issue/Capital Change (SHA). The document length is sufficient and contains detailed information about the share issuance under the incentive plan, not just a brief notice or a regulatory filing. Hence, the classification is SHA with high confidence.
2024-10-08 Chinese
关于获得创新药HSK21542注射液新适应症上市许可申请《受理通知书》的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the acceptance of a new drug indication application by the National Medical Products Administration (国家药品监督管理局). It details the drug, its clinical significance, and the regulatory acceptance notice. The document is short (1589 characters) and serves as a formal announcement of regulatory acceptance rather than a detailed financial or operational report. It does not contain financial statements, management discussion, or detailed investor presentation content. Therefore, it fits best as a Regulatory Filing (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-09-23 Chinese
关于获得创新药HSK46575片IND申请《受理通知书》的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from a pharmaceutical company about receiving an acceptance notice for an IND (Investigational New Drug) application for a new drug. It includes details about the drug, regulatory acceptance, and risk warnings. The document is short (1029 characters) and does not contain financial statements, management discussion, or detailed financial data. It is an announcement of a regulatory event related to drug development, not a financial report or detailed regulatory filing. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-09-23 Chinese
关于控股股东部分股份解除质押的公告
Major Shareholding Notification Classification · 95% confidence The document is an announcement regarding the release of pledged shares by a controlling shareholder of the company. It details the number of shares released from pledge, the shareholder's total pledged shares, and related information. There is no financial data, earnings information, or report attached. The content fits the category of a Major Shareholding Notification, as it concerns changes in significant share ownership or share pledging status by major shareholders.
2024-09-23 Chinese
北京市中伦（深圳）律师事务所关于海思科医药集团股份有限公司2024年限制性股票激励计划调整及授予相关事项的法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the adjustment and granting of a 2024 restricted stock incentive plan for a pharmaceutical company. It discusses legal compliance, approvals by the board and shareholders, and conditions for granting restricted stock. There are no financial statements, earnings data, or management discussion of financial results. The document is not an announcement of a report but a legal opinion related to a stock incentive plan. This fits best under Regulatory Filings (RNS) as it is a legal compliance document related to corporate governance and stock incentive plans, not a financial report or management announcement.
2024-09-19 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.